Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

MHRA may issue advice on capillary leak syndrome and AstraZeneca shot

The Medicines and Healthcare products Regulatory Agency (MHRA) is considering issuing precautionary advice for people with a history of capillary leak syndrome.

The medicines regulator has clarified that it does not see a causal link between the syndrome and AstraZeneca’s Covid-19 vaccine following a statement from the European Union that it was a rare side effect of the shot.


MHRA chief executive June Raine said that two of eight reports of capillary leak syndrome following AstraZeneca vaccination were in people with a history of the condition, and 40 million doses of the vaccine had been given.

Raine added: "The incidence of these reports is lower than the number of cases expected to occur by chance in the absence of vaccination of this extremely rare condition and the current evidence does not suggest that capillary leak syndrome is caused by the Covid-19 Vaccine AstraZeneca," she said.

"Whether or not a precautionary advice is warranted for patients who have previously experienced capillary leak syndrome is currently being carefully considered by the MHRA as well as the independent Commission on Human Medicines’ Covid-19 Benefit/Risk Expert Working Group."

The MHRA said on Thursday (June 10) that it “had received eight reports of capillary leak syndrome in the context of more than 40 million doses of the AstraZeneca vaccine given, and currently does not see a causal link.”

More For You

The NPA are calling on the government to include additional conditions, such as constipation

The NPA are calling on the government to include additional conditions, such as constipation

Pic credit: iStock

Pharmacy First has the potential to reach 20 million patients a year

An expansion of Pharmacy First to include more services could lead to a five time increase in the number of patients that are seen through the scheme, according to the National Pharmacy Association (NPA).

The NPA have urged the government to use the NHS 10 year plan, expected to be announced in the coming weeks, to deliver a ‘turbo charged’ Pharmacy First service which would allow pharmacists to treat a broader range of conditions and treat 20 million patients a year.

Keep ReadingShow less
The events are planned soon after the NHS 10-year Health Plan and Government Spending Review’s conclusion

The events are planned soon after the NHS 10-year Health Plan and Government Spending Review’s conclusion

Pic credit: iStock

Community pharmacy England workshops to take place in July

Community Pharmacy England is planning to discuss the future of the sector with pharmacy owners and LPCs through the regional Future of Pharmacy workshops, prior to the start of negotiations on the Community Pharmacy Contractual Framework (CPCF) for 2026/27.

The free-of-cost workshop will occur throughout the month of July in each NHS region for easy access. The invitation has been sent to all the pharmacy owners and their representatives.

Keep ReadingShow less
Students from retail sector using bursary aid for postgraduate education

The charity has given £28 million worth of financial aid to postgraduate students.

Bursary applications open for pharmacy students

A leading charity that provides financial aid for the families of those working in the pharmacy, convenience and grocery sector, has announced postgraduate bursary applications open for 2025/2026.

The Leverhulme Trade Charities Trust (LTCT) bursary scheme is open to students on postgraduate courses, whose parent, carer, spouse is employed in an eligible profession, such as convenience retailer, supermarket store worker, or pharmacy technician.

Keep ReadingShow less
Camizestrant Cuts Breast Cancer Progression by 50% – New Hope

There was a 56 per cent reduction in the risk of disease progression or death

Pic credit: iStock

Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts said on Sunday.

The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

Acute sore throats had the most consultations

Pic credit: istock

Pharmacy First has already seen over five million patients

The Pharmacy First scheme has helped over five million patients with minor illnesses, according to NHS England.

Around 2.4 million people received help without booking an appointment at their local pharmacy for seven common conditions including sore throat, earache or shingles.

Keep ReadingShow less